SATB1 and adenocarcinoma: Expression of SATB1 is associated with poor prognosis in pancreatobiliary type adenocarcinomas, and predicts response to adjuvant treatment in both intestinal type and pancreatobiliary type periampullary adenocarcinomas, including pancreatic cancer.